Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Miles

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Drugs|August 9, 2007
Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by David MilesDavid Miles
Clinical Breast Cancer|March 7, 2003
Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancerDavid Miles, Kostas Papazisis
Oncology|June 26, 2004
Setting the record straight: activity of gemcitabine monotherapy for breast cancerPeter Reichardt, David Miles
Expert Opinion on Biological Therapy|March 22, 2007
Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptorHannah M Simonds, David Miles
Breast Cancer Research : BCR|November 6, 2009
Update on the use of aromatase inhibitors in early-stage breast cancerGeorgios Kesisis, Andreas Makris, David Miles
Horticulture Research|April 16, 2025
Temporal dynamics and tissue-specific variations of the blueberry phyllosphere mycobiomeShay Lychen Szymanski, Timothy David Miles
Seminars in Oncology|October 19, 2004
Molecular approach to breast cancer treatmentYosef Yarden, José Baselga, David Miles
The Oncologist|November 28, 2002
Combination versus sequential single-agent therapy in metastatic breast cancerDavid Miles, Gunter von Minckwitz, Andrew D Seidman
Seminars in Oncology|October 19, 2004
Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda)Robert Leonard, David Miles, Peter Reichardt, et al.
Transfusion|October 22, 2014
Is undertransfusion a problem in modern clinical practice?Stephen Hibbs, David Miles, Julie Staves, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Drugs|August 9, 2007
Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by David MilesDavid Miles
Clinical Breast Cancer|March 7, 2003
Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancerDavid Miles, Kostas Papazisis
Oncology|June 26, 2004
Setting the record straight: activity of gemcitabine monotherapy for breast cancerPeter Reichardt, David Miles
Expert Opinion on Biological Therapy|March 22, 2007
Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptorHannah M Simonds, David Miles
Breast Cancer Research : BCR|November 6, 2009
Update on the use of aromatase inhibitors in early-stage breast cancerGeorgios Kesisis, Andreas Makris, David Miles
Horticulture Research|April 16, 2025
Temporal dynamics and tissue-specific variations of the blueberry phyllosphere mycobiomeShay Lychen Szymanski, Timothy David Miles
Seminars in Oncology|October 19, 2004
Molecular approach to breast cancer treatmentYosef Yarden, José Baselga, David Miles
The Oncologist|November 28, 2002
Combination versus sequential single-agent therapy in metastatic breast cancerDavid Miles, Gunter von Minckwitz, Andrew D Seidman
Seminars in Oncology|October 19, 2004
Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda)Robert Leonard, David Miles, Peter Reichardt, et al.
Transfusion|October 22, 2014
Is undertransfusion a problem in modern clinical practice?Stephen Hibbs, David Miles, Julie Staves, et al.
Pageof 6